The effect of digital interventions on related health literacy and skills for individuals living with chronic diseases: A systematic review and meta-analysis

Verweel, Lee; Newman, Anastasia; Michaelchuk, W.; Packham, Tara; Goldstein, Roger; Brooks, Dina

doi:10.1016/j.ijmedinf.2023.105114

Cited by 8 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, a notable study limitation is the potential variation in smartphone usage among participants. The study assumes a certain level of familiarity and consistent use of smartphones, which could introduce confounding factors if participants differ in their comfort and proficiency with such technology (i.e., digital literacy) [ 73 ]. Additionally, the success of the proposed approach relies on the widespread adoption and accessibility of smartphones and wearable sensors, which may not be universally available to all individuals undergoing rehabilitation [ 74 ].…”

Section: Discussionmentioning

confidence: 99%

Incorporating Wearable Technology for Enhanced Rehabilitation Monitoring after Hip and Knee Replacement

Lebleu,

Daniels,

Pauwels

et al. 2024

Sensors

View full text Add to dashboard Cite

Osteoarthritis (OA) poses a growing challenge for the aging population, especially in the hip and knee joints, contributing significantly to disability and societal costs. Exploring the integration of wearable technology, this study addresses the limitations of traditional rehabilitation assessments in capturing real-world experiences and dynamic variations. Specifically, it focuses on continuously monitoring physical activity in hip and knee OA patients using automated unsupervised evaluations within the rehabilitation process. We analyzed data from 1144 patients who used a mobile health application after surgery; the activity data were collected using the Garmin Vivofit 4. Several parameters, such as the total number of steps per day, the peak 6-minute consecutive cadence (P6MC) and peak 1-minute cadence (P1M), were computed and analyzed on a daily basis. The results indicated that cadence-based measurements can effectively, and earlier, differ among patients with hip and knee conditions, as well as in the recovery process. Comparisons based on recovery status and type of surgery reveal distinctive trajectories, emphasizing the effectiveness of P6MC and P1M in detecting variations earlier than total steps per day. Furthermore, cadence-based measurements showed a lower inter-day variability (40%) compared to the total number of steps per day (80%). Automated assessments, including P1M and P6MC, offer nuanced insights into the patients’ dynamic activity profiles.

show abstract

Section: Discussionmentioning

confidence: 99%

Incorporating Wearable Technology for Enhanced Rehabilitation Monitoring after Hip and Knee Replacement

Lebleu,

Daniels,

Pauwels

et al. 2024

Sensors

View full text Add to dashboard Cite

show abstract

“…In PV, low adherence was also more frequent in patients with low levels of education [36]. These ndings suggest that providing appropriate support and information to patients according to their health literacy and socioeconomic status may be crucial to improve adherence and reduce distress [37,38].…”

Section: Discussionmentioning

confidence: 99%

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Palandri,

Auteri,

Abruzzese

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. Methods The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. Results At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7% and 40.2% of patients, respectively. The main reason for low adherence was difficult ruxolitinib supply (49%), intentional (4.3%) and unintentional (46.7%) non-take. In multivariable regression analysis, low adherence was associated to male sex (p = 0.001), high distress (p < 0.001), and treatment duration ≥ 1 year (p = 0.03). Over time, rates of low adherence and high distress remained stable, but unintentional non-take decreased from 47.9–26.0% at week-48. MF patients with stable high adherence/low distress were more likely to obtain/maintain the spleen response at week-24. Conclusions Low adherence to ruxolitinib represents an unmet clinical need that require a multifaceted approach, based on reason behind it (patients characteristics and treatment duration). Its recognition may help distinguishing patients who are truly refractory and those in need of therapy optimization.

show abstract

“…Furthermore, a plethora of digital health applications have emerged to enhance HF care throughout the entire spectrum of the HF disease process, encompassing primary prevention, early detection, disease management, and the reduction of related morbidity (13,14). Digital tools and platforms have the potential to significantly impact patient outcomes by providing continuous support, personalised education, and real-time monitoring (15,16). Additionally, they can enhance treatment adherence and empower patients by offering access to resources, fostering self-management, and facilitating regular communication with healthcare providers (15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

“…Digital tools and platforms have the potential to significantly impact patient outcomes by providing continuous support, personalised education, and real-time monitoring (15,16). Additionally, they can enhance treatment adherence and empower patients by offering access to resources, fostering self-management, and facilitating regular communication with healthcare providers (15)(16)(17). Despite their proven efficacy in various healthcare contexts, limited attention has been given to the utilisation of such interventions in the context of PAH.…”

Section: Introductionmentioning

confidence: 99%

Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot study

Peñate,

Parra,

Morera

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

IntroductionDigital health interventions, particularly mobile health platforms, have shown promise in supporting patients with respiratory conditions, but their application in pulmonary arterial hypertension (PAH) remains limited. We aimed to assess the feasibility, acceptability, and potential clinical benefit of the novel PAHcare™ digital platform as a patient-centred intervention for PAH management through a prospective, single-arm, multicenter pilot study conducted on 53 patients diagnosed with PAH who used the platform for 6 months.MethodsThe primary objective was to assess the impact on Health-Related Quality of Life (HRQoL) through questionnaires. Secondary objectives included evaluating clinical outcomes, including disease progression, PAH signs and symptoms, the 6-min walking test, and the patient’s symptom perception. Additionally, we assessed patient satisfaction and engagement with the PAHcare™ platform, interaction with health coaches, retention, costs and healthcare resource utilisation (HCRU), and safety through monitoring device incidents.ResultsMinimal changes in HRQoL and clinical outcomes were observed over 6 months. A noteworthy 92.4% of patients actively used the platform in the first month, maintaining high usage throughout the study. Patient satisfaction was substantial, with more than half of the patients expressing excellence in service quality, willingness to reuse the platform, and fulfilment of their needs. Health coach interaction was high, with 76% of patients initiating contact within the first week. User retention rates were 70%, with prevalent ongoing usage and interaction with healthcare professionals even after the study. In terms of HCRU and costs, the study showed no significant changes in PAH-related hospital admissions, clinical visits, or tests. Finally, the low number of device-related incidents indicated platform safety.ConclusionThis pilot study provides compelling evidence supporting the feasibility and acceptability of the PAHcare™ digital platform to empower patients to manage their disease and significantly enhance their overall experience with PAH.

show abstract

The effect of digital interventions on related health literacy and skills for individuals living with chronic diseases: A systematic review and meta-analysis

Cited by 8 publications

References 56 publications

Incorporating Wearable Technology for Enhanced Rehabilitation Monitoring after Hip and Knee Replacement

Incorporating Wearable Technology for Enhanced Rehabilitation Monitoring after Hip and Knee Replacement

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot study

Contact Info

Product

Resources

About